Kensuke Egashira Selected Research

pitavastatin (itavastatin)

5/2022	Pitavastatin-Incorporated Nanoparticles for Chronic Limb Threatening Ischemia: A Phase I/IIa Clinical Trial.
1/2022	Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apoe-/- Mice.
1/2021	Nanoparticle-Mediated Simultaneous Targeting of Mitochondrial Injury and Inflammation Attenuates Myocardial Ischemia-Reperfusion Injury.
3/2020	Therapeutic Arteriogenesis/Angiogenesis for Peripheral Arterial Disease by Nanoparticle-Mediated Delivery of Pitavastatin into Vascular Endothelial Cells.
1/2020	Simultaneous targeting of mitochondria and monocytes enhances neuroprotection against ischemia-reperfusion injury.
11/2018	Nanoparticle-Mediated Targeting of Pitavastatin to Small Pulmonary Arteries and Leukocytes by Intravenous Administration Attenuates the Progression of Monocrotaline-Induced Established Pulmonary Arterial Hypertension in Rats.
8/2017	Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Left Ventricular Remodeling After Acute Myocardial Infarction by Inhibiting Monocyte-Mediated Inflammation.
7/2016	Anti-inflammatory Nanoparticle for Prevention of Atherosclerotic Vascular Diseases.
1/2016	A Translational Study of a New Therapeutic Approach for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin into Reperfused Myocardium Reduces Ischemia-Reperfusion Injury in a Preclinical Porcine Model.
1/2015	A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kensuke Egashira Research Topics

Disease

47	Inflammation (Inflammations) 01/2021 - 02/2002
22	Atherosclerosis 01/2022 - 01/2002
15	Myocardial Infarction 01/2021 - 12/2002
14	Ischemia 01/2021 - 09/2003
13	Atherosclerotic Plaque (Atheroma) 09/2017 - 04/2002
11	Infarction (Infarctions) 01/2019 - 12/2002
11	Fibrosis (Cirrhosis) 08/2007 - 02/2002
10	Neointima 12/2011 - 09/2006
8	Reperfusion Injury 01/2020 - 04/2003
8	Rupture 01/2018 - 03/2007
7	Heart Failure 08/2017 - 07/2002
7	Arteriosclerosis 10/2004 - 01/2002
6	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 05/2003
6	Ventricular Remodeling 08/2017 - 12/2002
6	Osteolysis 01/2017 - 08/2014
6	Vascular Diseases (Vascular Disease) 07/2016 - 01/2002
6	Thrombosis (Thrombus) 01/2013 - 04/2002
6	Hyperplasia 10/2004 - 06/2002
5	Vascular System Injuries 01/2020 - 06/2002
5	Pathologic Constriction (Stenosis) 01/2013 - 04/2002
4	Neoplasms (Cancer) 01/2021 - 01/2008
4	Pulmonary Arterial Hypertension 11/2018 - 05/2009
4	Acute Coronary Syndrome 01/2018 - 04/2002
4	Hypertension (High Blood Pressure) 02/2011 - 04/2002
4	Vascular Remodeling 02/2011 - 09/2003
4	Cardiovascular Diseases (Cardiovascular Disease) 04/2009 - 10/2002
3	Chronic Limb-Threatening Ischemia 05/2022 - 10/2012
3	Abdominal Aortic Aneurysm 01/2022 - 11/2004
3	Brain Ischemia (Cerebral Ischemia) 01/2020 - 12/2004
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017 - 02/2002
3	Insulin Resistance 06/2012 - 11/2002
3	Lung Injury 09/2011 - 07/2005
3	Hypertrophy 04/2004 - 07/2002
2	Peripheral Arterial Disease 03/2020 - 10/2012
2	Ischemic Stroke 01/2020 - 11/2003
2	Hypoxia (Hypoxemia) 04/2016 - 09/2004
2	Arthritis (Polyarthritis) 01/2016 - 08/2014
2	Pulmonary Hypertension 05/2015 - 11/2002
2	Left Ventricular Dysfunction 01/2015 - 07/2002

Drug/Important Bio-Agent (IBA)

46	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2017 - 01/2002
14	pitavastatin (itavastatin)FDA Link 05/2022 - 08/2010
13	Angiotensin IIIBA 01/2022 - 02/2002
12	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2018 - 11/2003
12	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2010 - 03/2002
11	Therapeutic UsesIBA 01/2021 - 04/2003
10	Apolipoproteins E (ApoE)IBA 01/2022 - 11/2004
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2003
8	ApolipoproteinsIBA 01/2022 - 01/2002
8	CytokinesIBA 01/2019 - 06/2002
8	LipidsIBA 01/2017 - 12/2004
8	CCR2 ReceptorsIBA 12/2011 - 04/2004
7	Transforming Growth Factor beta (TGF-beta)IBA 04/2004 - 03/2002
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2004 - 01/2002
6	Pioglitazone (Actos)FDA Link 01/2019 - 11/2002
6	ChemokinesIBA 01/2017 - 06/2002
6	Monocyte Chemoattractant ProteinsIBA 04/2009 - 02/2003
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2008 - 11/2002
5	MonocrotalineIBA 11/2018 - 05/2009
5	CholesterolIBA 07/2013 - 11/2003
5	Chemotactic FactorsIBA 10/2007 - 11/2002
5	NG-Nitroarginine Methyl Ester (L-NAME)IBA 02/2004 - 02/2002
4	Matrix Metalloproteinases (MMPs)IBA 03/2016 - 07/2002
4	Platelet-Derived Growth FactorIBA 05/2015 - 04/2007
3	Polylactic Acid-Polyglycolic Acid CopolymerIBA 05/2022 - 02/2014
3	Mitochondrial Permeability Transition PoreIBA 01/2021 - 02/2016
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2021 - 02/2016
3	SolutionsIBA 01/2019 - 11/2016
3	PPAR gammaIBA 01/2019 - 11/2002
3	Pharmaceutical PreparationsIBA 01/2017 - 10/2012
3	NF-kappa B (NF-kB)IBA 12/2015 - 07/2008
3	Imatinib Mesylate (Gleevec)FDA Link 05/2015 - 09/2008
3	Transcription Factors (Transcription Factor)IBA 08/2014 - 09/2003
3	Neutralizing AntibodiesIBA 06/2012 - 07/2002
3	Bleomycin (Blenoxane)FDA LinkGeneric 09/2011 - 05/2004
3	NF-kappaB decoyIBA 05/2009 - 12/2006
3	LigandsIBA 10/2007 - 11/2002
3	Interferon-gamma (Interferon, gamma)IBA 08/2007 - 03/2007
3	Messenger RNA (mRNA)IBA 06/2006 - 07/2002
3	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 02/2004 - 04/2002
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 12/2002
2	InterferonsIBA 01/2021 - 04/2007
2	glycolic acid (glycolate)IBA 01/2021 - 01/2016
2	HMGB1 Protein (HMG1)IBA 01/2019 - 06/2010
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2018 - 07/2005
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 08/2017 - 03/2002
2	AntioxidantsIBA 01/2017 - 07/2002
2	Ezetimibe (Zetia)FDA Link 01/2017 - 01/2012
2	Coenzyme A (CoA)IBA 01/2017 - 11/2003
2	OxysterolsIBA 10/2016 - 01/2012
2	Peptide Hydrolases (Proteases)FDA Link 07/2016 - 03/2016
2	Epoprostenol (Prostacyclin)FDA LinkGeneric 04/2016 - 02/2002
2	Peptides (Polypeptides)IBA 03/2016 - 03/2011
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 03/2016 - 10/2012
2	ultra-high molecular weight polyethylene (UHMWPE)IBA 03/2015 - 08/2014
2	FibrinIBA 01/2013 - 12/2006

Therapy/Procedure

19	Therapeutics 01/2021 - 04/2003
11	Stents 01/2013 - 03/2003
6	Replacement Arthroplasty 01/2017 - 08/2014
5	Intravenous Administration 01/2019 - 02/2014
3	Intramuscular Injections 03/2020 - 06/2009